Third U.S. patent covering Histotype Px® methods and applications granted
OSLO – May 19, 2025 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that U.S. patent 12,293,295 has been granted by the U.S. Patent and Trademark Office (USPTO).
This patent constitutes an important milestone as it is the first grant in the second patent family and expands the coverage for our technology and products. It is the third patent granted in the U.S. and together these patents provide strong protection of the novel methods underpinning DoMore Diagnostics’ digital Histotype Px biomarkers’ ability to provide prognostic evaluation and treatment decision support to cancer patients.
Torbjørn Furuseth, MD, Co-Founder and CEO at DoMore Diagnostics, commented,
"I am delighted that the USPTO has granted a patent in our second patent family related to our Histotype Px® digital biomarkers, significantly expanding the scope of protection of our methods and their application in a key strategic market. This patent grant reflects the ongoing commitment of DoMore Diagnostics to securing comprehensive intellectual property rights for our core technologies, and further reinforces our first mover advantage and leadership position in digital pathology and AI-based outcome prediction.”
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com